Genscript Biotech Corporation
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Weihui Shao
- Full Time Employees
- 5,568
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Jiangning Science Park Nanjing People's Republic of China 211100
- IPO Date
- Sep 28, 2017
- Website
- genscript.com
- Similar Companies
- Business
- Genscript Biotech Corporation (GNNSF) provides gene synthesis, peptide synthesis, protein and antibody production, and custom assay development services to pharmaceutical, biotechnology, and academic research customers worldwide. The company offers proprietary platforms including GenSmart for codon optimization and protein engineering; Phage Display Libraries for antibody discovery; and BestSelect for expression system selection, alongside catalog products such as recombinant proteins, antibodies, and CRISPR reagents under brands like SnapGene software and GenArt gene synthesis. Founded in 2002 and headquartered in Nanjing, China, with significant operations in the United States, Europe, and Asia-Pacific regions, Genscript serves the life sciences industry through segments focused on biologics development, contract research organization services, and industrial synthetic biology solutions. In recent developments, the company expanded its cell therapy manufacturing capabilities through a strategic partnership with a leading CDMO in 2024 and launched AI-driven protein design tools as part of its GenMachine platform in early 2025, enhancing its position in precision medicine and synthetic biology markets.
Genscript Biotech Corporation (GNNSF) Q4 2025 Earnings Call Transcript
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Genscript Biotech Corporation (GNNSF) Q2 2025 Earnings Call Transcript
GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation
GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader
GenScript Biotech Corporation Reports FY 2024 Results
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development
GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia
GenScript Biotech Corporation (GNNSF) Q2 2024 Earnings Call Transcript
GenScript Biotech Reports First Half 2024 Results
GenScript Biotech Corporation Launches FLASH Gene Service: The Fastest and Most Affordable Gene Synthesis Solution on the Market
GenScript Biotech Shares Drop After U.S. Lawmakers Scrutinize Chinese Ties
US lawmakers ask FBI for briefing on GenScript Biotech's links to China
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing
GenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing
GenScript Biotech officially joins SBTi to fulfill its sustainability commitment
GenScript Biotech Receives EcoVadis Bronze Medal for Outstanding Sustainability Performance
GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%